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Objective: Patients with pancreatic cancer (PDAC) who undergo surgical resection and 
receive effective chemotherapy have the best chance of long-term survival. Unfortunately, 
we lack predictive biomarkers to guide optimal systemic treatment. Ex-vivo generation of 
patient-derived organoids (PDO) for pharmacotyping may serve as predictive biomarkers in 
PDAC. The goal of the current study was to demonstrate the clinical feasibility of a PDO-
guided precision medicine framework of care. 
Methods: PDO cultures were established from surgical specimens and endoscopic 
biopsies, expanded in Matrigel, and used for high-throughput drug testing (pharmacotyping). 
Efficacy of standard-of-care chemotherapeutics was assessed by measuring cell viability 
after drug exposure. 
Results: A framework for rapid pharmacotyping of PDOs was established across a multi-
institutional consortium of academic medical centers. Specimens obtained remotely and 
shipped to a central biorepository maintain viability and allowed generation of PDOs with 
77% success. Early cultures maintain the clonal heterogeneity seen in PDAC with similar 
phenotypes (cystic–solid). Late cultures exhibit a dominant clone with a pharmacotyping 
profile similar to early passages. The biomass required for accurate pharmacotyping can be 
minimized by leveraging a high-throughput technology. Twenty-nine cultures were 
pharmacotyped to derive a population distribution of chemotherapeutic sensitivity at our 
center. Pharmacotyping rapidly-expanded PDOs was completed in a median of 48 (range 
18–102) days.  
Conclusions: Rapid development of PDOs from patients undergoing surgery for PDAC is 
eminently feasible within the perioperative recovery period, enabling the potential for 
pharmacotyping to guide post-operative adjuvant chemotherapeutic selection. Studies 





Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a limited 5-year 
overall survival that is driven by nearly universal systemic spread1. Even when amenable to 
complete surgical resection, systemic disease recurrence is common and the response to 
chemotherapy is a key driver of overall prognosis2,3. Furthermore, a favorable response to 
systemic chemotherapy in patients with locally advanced disease (i.e. ‘induction 
chemotherapy’) may enable surgical utilization along a potentially curative paradigm in 
selected settings4–6. Two combination chemotherapy regimens are currently viewed as 
standards for systemic therapy in PDAC, each with an approximately 30% response rate: 
gemcitabine plus nab-paclitaxel and FOLFIRINOX (5-fluorouracil, folinic acid, irinotecan and 
oxaliplatin)7–9. Despite these two options as standard of care in PDAC, there are no 
predictive biomarkers of treatment response available to distinguish patients that may 
benefit from one or the other. Tractable precision medicine strategies are needed to select 
an optimal systemic therapy for each patient in order to increase the durability of post-
surgical disease-free survival and enable more aggressive surgical utilization in the 
borderline resectable and locally advanced patient cohort. 
There are a number of putative biomarkers for clinical response that have been 
proposed for PDAC10–12. Most are based upon a gene mutation, gene expression or protein 
analysis, and are limited by challenges in describing the broader phenotypic behavior 
resulting from the holistic interplay inherent in cellular processes that drive cancer biology. A 
system that recapitulates each patient’s tumor as a model organism may enable this broad 
phenotypic assessment and facilitate rapid ex-vivo personalized drug testing13,14. Options for 
tumor modeling include two-dimensional cell lines, murine xenografts and three-dimensional 
patient-derived cultures, commonly termed organoids. Patient-derived organoids (PDOs) are 
self-organizing, three-dimensional structures that can be cultured from tumor specimens with 
a high rate of success15. Our previous work demonstrated that PDOs are an efficient model 
for molecular characterization in PDAC and may aid in the selection of an optimal 
chemotherapy regimen for each patient16,17.  
	
	
Several barriers have limited tumor-model based precision medicine approaches. 
First, the traditional patient-specific models of disease (i.e. 2D cell lines or xenografts) are 
limited by relatively low rates of success. Second, the time required to generate patient-
derived 2D lines and xenografts can often exceed 9–18 months. This is too long for patients 
to derive benefit in PDAC. In this work, we aim to show the feasibility of PDO-based 
precision medicine. In order to do this we needed to prove that: (1) PDOs can be 
established, expanded, and characterized from tissue acquisition protocols that exist within 
current frameworks of care; (2) the interval between tissue acquisition and ex-vivo 
pharmacotyping can be expedited to fit within a clinically meaningful time frame; and (3) a 
population distribution of ex-vivo PDO chemotherapeutic response can be generated to 
provide data suggesting unique chemotherapeutic sensitivities for each patient. Herein we 
demonstrate the ability to: (1) generate PDOs from endoscopic biopsies and surgical 
specimens; (2) complete pharmacotyping prior to start of adjuvant therapies; and (3) derive 
a population distribution of chemotherapeutic response suggesting unique therapeutic 
sensitivities for each patient, thus establishing PDO as a potentially important tool in patients 
undergoing multimodality treatment of localized PDAC.  
 
Methods 
Patients and tumor specimen collection 
Patients with a presumed or confirmed diagnosis of PDAC were eligible for 
enrollment onto IRB-approved tissue acquisition protocols at Johns Hopkins Hospital and 
Massachusetts General Hospital (MGH). For those undergoing surgery, portions of the 
tumor were harvested by a research pathologist following resection. To evaluate the 
capacity to establish PDOs from core needle specimens, tissue was obtained during 
diagnostic endoscopic ultrasound-directed biopsy as part of a multi-institutional clinical trial 
(NCT03563248). Tissues obtained off-site were shipped on ice overnight via commercial 




Organoid establishment and maintenance culture 
Biopsied tissue was dissociated to single cells with mechanical digestion in human 
wash media. Surgical tumor pieces were minced with a scalpel and digestion was carried 
out using a combination of mechanical dissociation and enzymatic digestion. Single cells 
were suspended in liquid Matrigel, plated in domes and covered with human complete 
feeding media. Cultures were incubated at 37°C with 21% of O2 and 5% of CO2 and 
passaged for cell line expansion or characterization biweekly. Complete protocol details are 
in keeping with prior work performed by our group16. 
 
Clinically relevant characterization: Genomics and gene expression analysis 
KRAS mutational status of PDOs were determined using next-generation sequencing 
(NGS) in methods similar to prior work18. In short, PDO DNA was isolated using the Tissue 
Preparation System (Siemens Healthineers, Erlangen, Germany) with Versant Tissue 
Preparation reagents (Siemens Healthineers). NGS was performed on the Ion S5-XL 
System (Life Technologies, Carlsbad, CA, USA). KRAS mutation calling was performed with 
the Ion Torrent Variant Caller Plugin (v5.2.1.39) for Torrent Suite software (v5.2). The limit of 
detection was set at 2%. Fishplot of genomic evolution was visualized using R studio 
(version 1.2.5033). 
RNA extraction was carried out with the AllPrep DNA/RNA/Protein Mini kit (80004, 
Qiagen, Hilden, Germany). Amplified cDNA was generated using the SMART-Seq® HT Kit 
(634437, Takara Bio USA, Mountain View, CA, US). PCR product was purified with a 1.8X 
Agencourt AMPure XP bead cleanup (Beckman Coulter), validated and quantified using the 
KAPA Library Quantification Kit for Illumina® Platforms (KK4824, Roche, Wilmington, MA) 
and pooled after tagging at equal concentrations as determined using the KAPA Library 
Quantification Kit for Illumina® Platforms. Sequencing was performed on a NextSeq 500 
system (Illumina) using a high output flow cell and 2 × 75 paired end reads. Reads were 
aligned to the hg38 genome using the STAR version 2.4.0h aligner (Alex Dobin, 
https://github.com/alexdobin/STAR) and counted using htseq-count in the intersection-strict 
	
	
mode against the Homo_sapiens.GRCh38.79.gtf annotation table from Ensembl (Hinton, 
Cambridge, United Kingdom, www.ensembl.org). After normalization, Collisson19 and 
Moffitt20 classifier gene expression was characterized and illustrated by heat maps. 
 
Clinically relevant characterization: Pharmacotyping 
Organoids were dissociated into single cells and plated on a 384-well assay plate in 
10% Matrigel. After a 48-hour recovery period, chemotherapeutics were administered using 
a semi-automated D300e dispenser (Tecan, Männedorf, Switzerland), normalized to 0.5% 
DMSO. Chemotherapeutics were tested across a logarithmically designed curve: 
gemcitabine, paclitaxel and irinotecan (range: 8.0 x 10-12 mol/L to 2.0 x 10-6 mol/L), and 5-FU 
and oxaliplatin (range: 1.0 x 10-8 to 1.0 × 10-4 mol/L). Negative controls included wells with 
DMSO normalization alone. Cell viability was assessed at 5 days using CellTiter Glo 
(Promega Corp, Madison, WI, USA)21. Viability curves were fitted using nonlinear logistic 
regression with Prism v8 (GraphPad Software, La Jolla, CA, US). Normalized area under 
curve (AUC) was obtained by dividing the AUC value by the maximum area for each 
concentration range. A population distribution was illustrated by collective analysis of each 
chemotherapeutic using a violin plot (R studio version 1.2.5033). Pharmacotyping was 
performed in four biologic replicates, and at least two technical replicates with most 
performed at early and late passage.  
 
Results 
PDOs can be established, expanded and characterized from tissue acquisition 
protocols that exist within current frameworks of care 
We propose a classification schema for PDO culture maturation in three clinically 
relevant phases: establishment, expansion, and characterization (Figure 1A-C). The 
establishment phase describes the emergence of viable ductal organoid structures in the 
setting of ductal cell selection. Throughout the establishment phase, the culture may contain 
biomass derived from either normal ducts, PDAC, or both. Expansion is characterized by 
	
	
increasing biomass accumulation, or ‘growth’, in a relatively pure ductal cell culture. This 
phase varies in duration as each PDO culture has a unique growth rate based on poorly 
understood growth regulatory mechanisms. The characterization phase is a descriptor used 
to infer that a critical biomass has been reached allowing for molecular characterization or 
phenotypic analysis without threatening the continued passage and expansion of the PDO 
line.   
In total, patient-derived tumor tissues were received for 76 patients (77 specimens; 
one patient had both biopsy and surgery), of which 16 (21%) received neoadjuvant or 
induction chemotherapy (7 FOLFIRINOX and 5 gemcitabine with nab-paclitaxel). Thirty-two 
surgical specimens were received, three were received fresh from endoscopic biopsies 
performed within our institution, and 42 were obtained from our multi-institutional 
collaboration. Successful establishment occurred in 77% (59/77, Figure 1D) as determined 
by emergence of organoid structures growing within 1–3 passages of initial plating. 
Establishment was similar for tissues derived from biopsy (35/45, 78%) and for samples 
from resection (24/32, 75%; p=n.s.).   
The expansion phase appeared to be the most variable amongst our PDO set. Both 
the phenotype and speed at which lines expand are likely a reflection of the underlying 
biology of the line and goals for PDO characterization. For example, if aliquots of early 
passages are committed to downstream molecular analysis, the biomass available for 
expansion is reduced. Overall, cultures fail to transition from expansion phase to 
characterization one third of the time (19/59, 32%; Figure 1D). The reasons for failure to 
expand included 1) suspected “contamination” of the culture by growth of biomass derived 
from the normal ductal epithelium based on morphology (6/19), 2) suspected microbial 
contamination and removal from our sterile living biobank based on visual inspection (5/19), 
and 3) unclear loss of biomass likely due to disease biology and dependence (or lack 
thereof) upon growth factors in our PDAC-specific media (8/19). At the time of this analysis, 
additional 19% to those already characterized remain viable in the expansion phase with 
plans for characterization. Molecular characterization was initiated for half of the cultures 
	
	
(29/59; 49%) that were successfully established. The phenotypes vary from cystic to solid in 
nature with the capacity to preserve heterogeneity in phenotype in most cultures, and do not 
differ between biopsy- or surgery-derived organoids (Figure 1E). 
 
Organoids enable molecular classification through gene expression analysis 
As a proof of principle, fourteen PDOs underwent RNA sequencing and supervised 
gene expression clustering for subtype classification (Figure 2A-D). Similar to work done by 
others, clustering our ex-vivo lines based upon the strategy devised by Collison et al. 19 
revealed the epithelial and quasi-mesenchymal (QM) subtypes (Figure 2A). Though isolated 
expression was found in some exocrine-like genes, no lines clustered predominantly into this 
subtype. These data support the notion that PDAC subtyping methods resulting in the 
original definition of an exocrine-like subtype may have been influenced by normal tissue 
contamination in samples with low cellularity22.  
Given the similarities in supervised clustering done by Collison et al and Moffitt et al., 
most epithelial lines resembled the classical PDAC subtype using the Moffitt approach 
(Figure 2C)20. The PDO clustering most strongly with QM, as expected, demonstrated a 
gene expression profile consistent with the basal-like subtype by Moffitt.  
 
Defining tumor-associated mutation burden and clonality 
Targeted sequencing was performed in a laboratory certified for clinical use 
according to the Clinical Laboratory Improvement Amendments (CLIA) by the Centers for 
Medicare and Medicaid Services. Confirmation of malignancy and assessment of clonality 
was undertaken via longitudinal analysis of mutational profile during early organoid culture. 
The nearly ubiquitous KRAS mutation confirms the organoid culture’s biomass derived from 
a pancreatic malignancy (Figure 3). While the initial processing of a tumor’s tissue may 
result in ‘normal’ (i.e. non-cancerous) cell contamination, the biomass present in a 
successful culture is derived principally from malignant tissue. Mutation profiling and mutant 
allele frequency (MAF) analysis can be used to assess the capacity to preserve source-
	
	
tissue heterogeneity. In organoid JHH 111, for example, longitudinal assessment of MAF 
based upon KRAS from passages 1 to 5 suggested clonal heterogeneity of the original 
tumor can be maintained in early culture. In the first passage of the PDO culture, variants 
G12V and G12D and G12R were present with MAF of 33%, 9% and 1%, respectively, in 
addition to wild type allele. By passage three, variant G12R appeared with 43% allele 
frequency, and became the dominant clone of the culture by passage 4 (Figure 3). With 
unbiased collective culture of this line, a dominant clone matures (G12R) in the culture over 
time. This clone was the only one identified by CLIA-certified somatic testing of bulk primary 
tumor. 
 
The interval between tissue acquisition and ex-vivo pharmacotyping can be expedited 
to fit within a clinically meaningful time-frame 
Following our initial efforts to confirm the tumor-derived nature of these organoids 
(KRAS testing) and the capacity to derive gene-expression based subtype (RNA-seq), we 
next sought to assess the capacity to perform direct drug-testing (i.e., pharmacotyping) in a 
clinically relevant time frame. We have previously demonstrated the capacity to 
pharmacotype organoid lines which are well established and late in passage.16 In this work, 
we first assessed the stability of pharmacotyping profiles, or drug sensitivity, in early 
passage PDOs (Figure 4A) as compared to late passage organoids derived from the same 
tumor (Figure 4B). With clonality established within the first set of passages, we found the 
dominant clone of a PDO line’s early passage to have a pharmacotyping profile that is 
similar to the later, more established PDO. This pattern was validated in over a dozen 
samples with 7 to 89 days between passages (Figures 4C-E, supplementary figures 1A–B, 
supplementary tables S1–5). In some, AUC increased marginally at later passage, most 
noticeably when exposed to gemcitabine. The mean AUC difference between technical 
replicates at early and late passage was 0.083 (standard deviation ±0.12) in gemcitabine 
and 0.054 ±0.12 in paclitaxel testing. Irinotecan demonstrated the least variance between 
	
	
early and late testing with a mean difference of 0.009 ±0.076. Work is continuing to 
investigate the influence of potential batch effects and clonality on these findings. 
We then assessed the minimum amount of biomass required to carry out 
pharmacotyping in a high-throughput fashion. With an eye towards liquid handling robotics 
and drug printer technology we selected a 384-well format and varied biomass from 25 to 
1000 cells per well (Figure 5A). Pharmacotyping assessment demonstrated similar drug-
sensitivity across all conditions (Figure 5B-D, supplementary table S6). 
Next, we tested the capacity to establish a pharmacotyping profile within a clinically 
relevant time frame. In a surgery-first approach to disease management, a common clinical 
goal is to begin adjuvant therapy within 8–12 weeks of the operative date. We proceeded 
with a series of patient-derived samples that were processed and expanded with the primary 
goal of rapid pharmacotyping. Biomass expansion during passage was found to be highly 
variable between specimens. We suspect this is due to underlying molecular determinants 
yet to be elucidated. When focused on rapid pharmacotyping, drug testing can usually be 
performed within the first 5 passages. In our hands, pharmacotyping was possible to perform 
in as few as 18 days (Figure 5E). The mean time to pharmacotyping was 49 days (range 
18–102 d, median 48d). A survey of our pancreatectomy database revealed the median time 
between surgery and initiation of chemotherapy was 62 days during the same period. 
 
A population distribution of ex-vivo PDO chemotherapeutic response can be 
generated to provide data suggesting unique chemotherapeutic sensitivities for each 
patient. 
Dose-viability curves for gemcitabine, paclitaxel, irinotecan, 5-FU and oxaliplatin 
showed substantial inter-patient heterogeneity in chemosensitivity. Normalized AUC 
describing the relative sensitivity of the patient-derived organoid cultures showed a wide 
population distribution for all single agents tested (Figure 6A-E). Integrating data from 
previously conducted clinical trials suggesting chemotherapeutic sensitivity in approximately 
one-third of patients (and overt resistance in one-third)7,23, we clustered the population 
	
	
distribution into thirds to evaluate the capacity to discriminate sensitivity from resistance. 
One patient received FOLFIRINOX and one gemcitabine-paclitaxel before the PDO 
establishment, whereas 27/29 were treatment naïve. Putative gemcitabine sensitivity was 
reflected by an AUC value of 0.32 ±0.042 (mean ±SD). Putative gemcitabine resistance, in 
contrast, was defined by an AUC value of 0.54 ±0.060. Similar values can be derived for 
each chemotherapy: paclitaxel (sensitivity 0.27 ±0.035, resistance 0.56 ±0.059), irinotecan 
(sensitivity 0.28 ±0.030; resistance 0.48 ±0.063), 5-FU (sensitivity 0.53 ±0.065; resistance 
0.75 ±0.028), and oxaliplatin (sensitivity 0.73 ±0.052; resistance 0.85 ±0.014). The therapies 
with the greatest discriminatory capacity using an ex-vivo PDO-guided approach appeared 
to be gemcitabine, paclitaxel, irinotecan and 5-FU. The oxaliplatin population distribution, in 
contrast, appeared to have only two outliers amongst a set of otherwise homogenous 
responses. As an example, the only basal-like PDO was among the most sensitive to 
gemcitabine (AUC 0.26, 95% confidence interval [0.21–0.31]), paclitaxel (0.27 [0.25–0.29]), 




PDO pharmacotyping has potential for future use as a means of personalized 
therapeutic selection for PDAC patients. In this work, we show the feasibility of PDO-based 
precision medicine by demonstrating that: (1) PDOs can be established, expanded, and 
characterized from existing tissue acquisition protocols within current frameworks of care; (2) 
the interval between tissue acquisition and ex-vivo pharmacotyping can be expedited to fit 
within a clinically meaningful time frame; and (3) a population distribution of unique ex-vivo 
PDO chemotherapeutic response discriminate subsets of sensitivity and resistance. Patient-
derived tissues, from resection or biopsy, can be utilized to rapidly establish an ex-vivo 
personalized model of PDAC. Prospective validation of this approach is underway as an 
	
	
integrated translational research component of a multi-center randomized clinical trial 
(NCT03563248, Figure 7).  
In a subset of PDOs selected for rapid pharmacotyping, the median time required to 
produce drug response data was shorter than the corresponding time to initiation of 
chemotherapy in the clinic. The time to pharmacotyping depends upon the biomass diverted 
from culture to acquire early passage mutation or gene expression data. The time interval 
can also be shortened if the desire to maintain a line as an immortalized research resource 
is not a primary aim. When these data are evaluated in aggregate, rapid pharmacotyping 
may be a clinically tractable strategy for precision medicine in PDAC.  
Pharmacotyping our living PDO biobank results in the generation of a population 
distribution of chemotherapeutic efficacy that appears similar to that seen in our patients and 
suggests that this ex-vivo distribution may recapitulate the clinical response. In prior work 
involving 66 patients, 9 were identified in retrospective clinical follow-up16. Five of 9 patients 
were treated with chemotherapeutics to which their PDO showed unique sensitivity. These 
patients had better than average progression-free survival. Two of three patients that 
progressed rapidly had a PDO demonstrating resistance to the therapies selected in their 
clinical care. These retrospective data are in keeping with other work in gastrointestinal 
cancers demonstrating correlation between PDO pharmacotype and clinical response24–26.  
Though we and others have previously demonstrated that PDOs are able to 
recapitulate the somatic mutation profile of the primary tumor, the capacity to preserve 
intratumoral heterogeneity in early passage has been debated26,27. In the current study, we 
demonstrate that intratumoral heterogeneity is represented in early passage cultures. A 
dominant clone does emerge in culture. The capacity to propagate with heterogeneity, and 
the speed at which a dominant clone emerges, is likely dependent upon the starting tissues 
and the underlying tumor biology. Similar to prior work, we did not encounter clonal drift in 
longer term cultures (passages 3–5, months 2–5)28,29. These data also suggest an intriguing 
clinical use for PDOs. As this technique enriches the ductal component, a somatic 
mutational analysis can be used to detect lower-frequency and targetable mutations that 
	
	
cannot be detected in the diagnostic gene panels from bulk primary tumor due to low 
cellularity and excess stromal ‘contamination’. On the other hand, in developing an 
immortalized culture derived from the ductal epithelium alone, the TME and immune infiltrate 
fail to propagate into later passages. Therefore, when gene-expression subtyping in later 
passages is performed, the data would not be expected to capture the proposed PDAC 
subtypes whose methods are dependent upon bulk RNA analysis of whole tumor. This 
includes the ability to capture the immunogenic subtype originally proposed by Bailey et 
al.30, and the ability to determine stromal classification31.  
There are several limitations to this work. First, this experience highlights several 
opportunities for improvement in methodology for future consideration. Pitfalls were common 
during establishment and resulted in the identification of several opportunities for 
improvement in both logistic and technical domains. Logistic challenges for multi-site 
collaboration included eliminating variation in collection methodology, streamlining 
processes to ensure efficient transfer of specimens to commercial shipping services, 
maintaining viability and sterility through the shipping process, and timely specimen receipt 
at our centralized laboratory. Technical opportunities for improvement resulted in a reduced 
reliance upon enzymatic digestion for core needle biopsy specimens. We are also cautious 
at this juncture to propose current clinical utilization of PDO pharmacotyping. We endorse 
the position that ethical use requires prospective validation in PDAC. Additionally, using 
PDOs in clinical decision making will be subject to regulatory requirements and clinical 
laboratory certification in most jurisdictions. There are several agents in the healthcare 
environment who have begun to work in this direction in anticipation of prospective validation 
of PDOs as predictive biomarkers of clinical response.  Finally, the pace of organoid growth 
and pharmacotyping could be further accelerated for routine use in the neoadjuvant or 
metastatic setting. 
A clinical framework, in which PDOs are efficiently generated from surgical 
specimens or endoscopic biopsies and characterized by pharmacotyping, can be 
established at academic medical centers with integrated research facilities. Our work 
	
	
demonstrates that this approach is a tractable strategy to facilitate precision medicine in the 
treatment of pancreatic cancer. Prospective studies to assess correlation between clinical 
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1. Phases of organoid culture include (A) establishment of the culture, (B) expansion of 
the biomass and (C) reaching a critical biomass needed for molecular 
characterization and stabilization. (D) Patient-derived pancreatic cancer organoids 
can be established from surgical resection specimens and endoscopic ultrasound-
guided diagnostic biopsy cores with high success rate. (E) The late cultures present 
a characteristic growth pattern that remains stable. The appearance of organoid 
culture does differ between the sources of original tumor tissue.  
 
2. PDOs can be utilized to assess PDAC subtype using established methods based 
upon RNA sequencing. (A) Heat map describing RNA gene expressions used to 
derive Collison et al. PDAC classification schema19,32. PDO listed above with gene 
and Collison subtype detailed along the left. (B) Supervised gene expression 
clustering schema from Collison et al. (C) Heat map detailing gene expression used 
to derive PDAC subtype according to the Moffitt classification20. (D) Supervised gene 
	
	
expression clustering according to the Moffitt classification. 
 
3. Patient-derived organoid JHH111 clonal heterogeneity illustrated in fishplot. Notably, 
the KRAS variant G12R becomes a dominant clone in the culture and is the only 
clone noted on CLIA testing of the primary tumor. 
 
4. Pharmacotyping data from early passage PDOs present similar profiles as from late 
passage PDOs. (A) PDO 201 pharmacotyping data at passage 6 (p6) with drug 
response curves generated for the five standard of care agents used in the clinical 
	
	
treatment of PDAC. (B) PDO 201 pharmacotyping data at passage 12 (p12) against 
the same agents demonstrates similar drug response curves. PDO sensitivity to 
exposure to (C) gemcitabine, (D) paclitaxel and (E) irinotecan in paired PDO cultures 
with interval between early (blue) and late (red) pharmacotyping dates, measured in 
days, marked along the x-axis. Chemotherapeutic sensitivity is represented as an 
area under the curve (% or 0–1). 
 
5. Minimizing biomass needed for pharmacotyping may enable rapid drug testing in a 
clinical setting. (A) Photomicrograph of high-throughput culture plates containing 25, 
100, 500 and 1000 cells per well. Cell survival upon exposure to (B) gemcitabine, (C) 
paclitaxel and (D) irinotecan with 25, 100, 500 and 1000 cells per well. (E) The 
interval between clinical specimen acquisition and pharmacotyping can be minimized 
by leveraging high-throughput technology and minimizing the biomass required for 
pharmacotyping. Time to pharmacotyping measured in days along x-axis for each 
	
	
PDO. Passage duration noted along bar graph by colors. 
 
6. (A-E) Inter-patient variation of chemotherapy response can be captured in the 
population distribution of PDO cultures. The commonly used chemotherapeutic 
agents (gemcitabine, paclitaxel, irinotecan, 5-fluorouracil and oxaliplatin) show a 




7. Rationale for precision medicine using patient-derived organoid expansion to 
characterize tumor.  
(A) Pre-treatment core needle biopsies are acquired during a diagnostic endoscopic 
ultrasound. (B) Patient receives neoadjuvant or induction chemotherapy before (C) 
surgical resection of the primary tumor. (D) Biopsy-derived tumor cells can be grown 
into an organoid with a high success rate. A new PDO can be similarly established 
from the surgical specimen to recapitulate possible changed signature in resistance. 
(E) After neoadjuvant treatment, clinical response to therapeutic regimen can be 
compared to chemosensitivity profile of the PDO, and to (F) inform adjuvant 
chemotherapy selection based on the results of pharmacotyping of the patient-
specific culture. 
 
 
 
